Safety and efficacy of botulinum toxin type B (Myobloc) in adductor spasmodic dysphonia.
Identifieur interne : 000F37 ( Ncbi/Merge ); précédent : 000F36; suivant : 000F38Safety and efficacy of botulinum toxin type B (Myobloc) in adductor spasmodic dysphonia.
Auteurs : Charles H. Adler [États-Unis] ; Stephen F. Bansberg ; Kari Krein-Jones ; Joseph G. HentzSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 2004.
English descriptors
- KwdEn :
- Adult, Botulinum Toxins (administration & dosage), Botulinum Toxins (therapeutic use), Dose-Response Relationship, Drug, Female, Humans, Injections, Male, Middle Aged, Neuromuscular Agents (administration & dosage), Neuromuscular Agents (therapeutic use), Severity of Illness Index, Vocal Cords (physiopathology), Voice Disorders (diagnosis), Voice Disorders (drug therapy), Voice Disorders (physiopathology).
- MESH :
- chemical , administration & dosage : Botulinum Toxins, Neuromuscular Agents.
- chemical , therapeutic use : Botulinum Toxins, Neuromuscular Agents.
- diagnosis : Voice Disorders.
- drug therapy : Voice Disorders.
- physiopathology : Vocal Cords, Voice Disorders.
- Adult, Dose-Response Relationship, Drug, Female, Humans, Injections, Male, Middle Aged, Severity of Illness Index.
Abstract
This single-site, open-label, dose-finding study evaluated the safety and efficacy of botulinum toxin type B (BoNT-B; Myobloc) for the treatment of adductor spasmodic dysphonia (AdSD) in 13 patients. Three patients received a total of 50 U (25 U per vocal fold); the same three subsequently received 100 U, and then 10 more received 200 U. The primary measure of efficacy was the patient's rating of the change in the severity of spasms on a scale from -3 to +3. There were seven secondary measures of efficacy, including blinded ratings of the sound of voice recorded on audiotape. At Week 8 after injection, spasms improved in 0 of 3 patients who received 50 U, 1 of 3 patients who received 100 U, and 8 of 10 patients who received 200 U. The mean (+/- standard deviation [SD]) score for the change in spasm severity at Week 8 in the 200 U group was 1.4 (+/-1.2) points (P = 0.004). All seven secondary measures also showed improvement. Breathiness was the most common side effect but was mild in intensity and of short duration. We conclude that BoNT-B is safe and effective for the treatment of adductor spasmodic dysphonia.
DOI: 10.1002/mds.20098
PubMed: 15372600
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 003351
- to stream PubMed, to step Curation: 003351
- to stream PubMed, to step Checkpoint: 003314
Links to Exploration step
pubmed:15372600Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Safety and efficacy of botulinum toxin type B (Myobloc) in adductor spasmodic dysphonia.</title><author><name sortKey="Adler, Charles H" sort="Adler, Charles H" uniqKey="Adler C" first="Charles H" last="Adler">Charles H. Adler</name><affiliation wicri:level="2"><nlm:affiliation>Parkinson's Disease and Movement Disorders Center, Department of Neurology, Mayo Clinic Scottsdale, 13400 E. Shea Blvd., Scottsdale, AZ 85259, USA. calder@mayo.edu</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Parkinson's Disease and Movement Disorders Center, Department of Neurology, Mayo Clinic Scottsdale, 13400 E. Shea Blvd., Scottsdale, AZ 85259</wicri:regionArea><placeName><region type="state">Arizona</region></placeName></affiliation></author><author><name sortKey="Bansberg, Stephen F" sort="Bansberg, Stephen F" uniqKey="Bansberg S" first="Stephen F" last="Bansberg">Stephen F. Bansberg</name></author><author><name sortKey="Krein Jones, Kari" sort="Krein Jones, Kari" uniqKey="Krein Jones K" first="Kari" last="Krein-Jones">Kari Krein-Jones</name></author><author><name sortKey="Hentz, Joseph G" sort="Hentz, Joseph G" uniqKey="Hentz J" first="Joseph G" last="Hentz">Joseph G. Hentz</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2004">2004</date><idno type="RBID">pubmed:15372600</idno><idno type="pmid">15372600</idno><idno type="doi">10.1002/mds.20098</idno><idno type="wicri:Area/PubMed/Corpus">003351</idno><idno type="wicri:Area/PubMed/Curation">003351</idno><idno type="wicri:Area/PubMed/Checkpoint">003314</idno><idno type="wicri:Area/Ncbi/Merge">000F37</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Safety and efficacy of botulinum toxin type B (Myobloc) in adductor spasmodic dysphonia.</title><author><name sortKey="Adler, Charles H" sort="Adler, Charles H" uniqKey="Adler C" first="Charles H" last="Adler">Charles H. Adler</name><affiliation wicri:level="2"><nlm:affiliation>Parkinson's Disease and Movement Disorders Center, Department of Neurology, Mayo Clinic Scottsdale, 13400 E. Shea Blvd., Scottsdale, AZ 85259, USA. calder@mayo.edu</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Parkinson's Disease and Movement Disorders Center, Department of Neurology, Mayo Clinic Scottsdale, 13400 E. Shea Blvd., Scottsdale, AZ 85259</wicri:regionArea><placeName><region type="state">Arizona</region></placeName></affiliation></author><author><name sortKey="Bansberg, Stephen F" sort="Bansberg, Stephen F" uniqKey="Bansberg S" first="Stephen F" last="Bansberg">Stephen F. Bansberg</name></author><author><name sortKey="Krein Jones, Kari" sort="Krein Jones, Kari" uniqKey="Krein Jones K" first="Kari" last="Krein-Jones">Kari Krein-Jones</name></author><author><name sortKey="Hentz, Joseph G" sort="Hentz, Joseph G" uniqKey="Hentz J" first="Joseph G" last="Hentz">Joseph G. Hentz</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="2004" type="published">2004</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Botulinum Toxins (administration & dosage)</term><term>Botulinum Toxins (therapeutic use)</term><term>Dose-Response Relationship, Drug</term><term>Female</term><term>Humans</term><term>Injections</term><term>Male</term><term>Middle Aged</term><term>Neuromuscular Agents (administration & dosage)</term><term>Neuromuscular Agents (therapeutic use)</term><term>Severity of Illness Index</term><term>Vocal Cords (physiopathology)</term><term>Voice Disorders (diagnosis)</term><term>Voice Disorders (drug therapy)</term><term>Voice Disorders (physiopathology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Botulinum Toxins</term><term>Neuromuscular Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Botulinum Toxins</term><term>Neuromuscular Agents</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Voice Disorders</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Voice Disorders</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Vocal Cords</term><term>Voice Disorders</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Dose-Response Relationship, Drug</term><term>Female</term><term>Humans</term><term>Injections</term><term>Male</term><term>Middle Aged</term><term>Severity of Illness Index</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">This single-site, open-label, dose-finding study evaluated the safety and efficacy of botulinum toxin type B (BoNT-B; Myobloc) for the treatment of adductor spasmodic dysphonia (AdSD) in 13 patients. Three patients received a total of 50 U (25 U per vocal fold); the same three subsequently received 100 U, and then 10 more received 200 U. The primary measure of efficacy was the patient's rating of the change in the severity of spasms on a scale from -3 to +3. There were seven secondary measures of efficacy, including blinded ratings of the sound of voice recorded on audiotape. At Week 8 after injection, spasms improved in 0 of 3 patients who received 50 U, 1 of 3 patients who received 100 U, and 8 of 10 patients who received 200 U. The mean (+/- standard deviation [SD]) score for the change in spasm severity at Week 8 in the 200 U group was 1.4 (+/-1.2) points (P = 0.004). All seven secondary measures also showed improvement. Breathiness was the most common side effect but was mild in intensity and of short duration. We conclude that BoNT-B is safe and effective for the treatment of adductor spasmodic dysphonia.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">15372600</PMID><DateCreated><Year>2004</Year><Month>09</Month><Day>16</Day></DateCreated><DateCompleted><Year>2004</Year><Month>12</Month><Day>21</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>25</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-3185</ISSN><JournalIssue CitedMedium="Print"><Volume>19</Volume><Issue>9</Issue><PubDate><Year>2004</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>Safety and efficacy of botulinum toxin type B (Myobloc) in adductor spasmodic dysphonia.</ArticleTitle><Pagination><MedlinePgn>1075-9</MedlinePgn></Pagination><Abstract><AbstractText>This single-site, open-label, dose-finding study evaluated the safety and efficacy of botulinum toxin type B (BoNT-B; Myobloc) for the treatment of adductor spasmodic dysphonia (AdSD) in 13 patients. Three patients received a total of 50 U (25 U per vocal fold); the same three subsequently received 100 U, and then 10 more received 200 U. The primary measure of efficacy was the patient's rating of the change in the severity of spasms on a scale from -3 to +3. There were seven secondary measures of efficacy, including blinded ratings of the sound of voice recorded on audiotape. At Week 8 after injection, spasms improved in 0 of 3 patients who received 50 U, 1 of 3 patients who received 100 U, and 8 of 10 patients who received 200 U. The mean (+/- standard deviation [SD]) score for the change in spasm severity at Week 8 in the 200 U group was 1.4 (+/-1.2) points (P = 0.004). All seven secondary measures also showed improvement. Breathiness was the most common side effect but was mild in intensity and of short duration. We conclude that BoNT-B is safe and effective for the treatment of adductor spasmodic dysphonia.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Adler</LastName><ForeName>Charles H</ForeName><Initials>CH</Initials><AffiliationInfo><Affiliation>Parkinson's Disease and Movement Disorders Center, Department of Neurology, Mayo Clinic Scottsdale, 13400 E. Shea Blvd., Scottsdale, AZ 85259, USA. calder@mayo.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bansberg</LastName><ForeName>Stephen F</ForeName><Initials>SF</Initials></Author><Author ValidYN="Y"><LastName>Krein-Jones</LastName><ForeName>Kari</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Hentz</LastName><ForeName>Joseph G</ForeName><Initials>JG</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009465">Neuromuscular Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0Y70779M1F</RegistryNumber><NameOfSubstance UI="C096323">rimabotulinumtoxinB</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.24.69</RegistryNumber><NameOfSubstance UI="D001905">Botulinum Toxins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D001905">Botulinum Toxins</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000008">administration & dosage</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004305">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D007267">Injections</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D009465">Neuromuscular Agents</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000008">administration & dosage</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012720">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D014827">Vocal Cords</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000503">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D014832">Voice Disorders</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000503">physiopathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>9</Month><Day>17</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>12</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>9</Month><Day>17</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15372600</ArticleId><ArticleId IdType="doi">10.1002/mds.20098</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>États-Unis</li></country><region><li>Arizona</li></region></list><tree><noCountry><name sortKey="Bansberg, Stephen F" sort="Bansberg, Stephen F" uniqKey="Bansberg S" first="Stephen F" last="Bansberg">Stephen F. Bansberg</name><name sortKey="Hentz, Joseph G" sort="Hentz, Joseph G" uniqKey="Hentz J" first="Joseph G" last="Hentz">Joseph G. Hentz</name><name sortKey="Krein Jones, Kari" sort="Krein Jones, Kari" uniqKey="Krein Jones K" first="Kari" last="Krein-Jones">Kari Krein-Jones</name></noCountry><country name="États-Unis"><region name="Arizona"><name sortKey="Adler, Charles H" sort="Adler, Charles H" uniqKey="Adler C" first="Charles H" last="Adler">Charles H. Adler</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000F37 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 000F37 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:15372600
|texte= Safety and efficacy of botulinum toxin type B (Myobloc) in adductor spasmodic dysphonia.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:15372600" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |